Purchase this article with an account.
Tarek M Shaarawy, Florent Aptel, Henny J Beckers, Carroll A B Webers, Elisa Bluwol, José M Martínez-de-la-Casa, Julián García-Feijoó, Yves Lachkar, Carmen D. Méndez-Hernández, Isabelle Riss; 12-month interim results of a multicentre open-label study of the InnFocus MicroShunt® Glaucoma Drainage System in patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3457.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The InnFocus MicroShunt® Glaucoma Drainage System (MicroShunt) (8.5 mm long, 70 µm lumen) is made from SIBS (poly[styrene-block-isobutylene-block-styrene]). We present the 12-month interim analysis of a prospective, multicenter, open-label, 24-month study (NCT02177123), which evaluates the efficacy and safety of the MicroShunt in patients with primary open-angle glaucoma.
The study was conducted in France, The Netherlands, Spain and Switzerland. The MicroShunt was implanted ab externo with topical Mitomycin C (0.2–0.4 mg/mL) for 2–3 minutes, then rinsed with saline, in patients not controlled on maximum tolerated medical therapy with intraocular pressure (IOP) ≥18 and ≤35 mmHg. Primary outcomes were reduction in IOP from baseline to Month 12 (overall success: IOP <21 mmHg and ≥20% reduction with or without medications, no reoperation for glaucoma or loss of light perception) and incidence of device- and/or procedure-related adverse events (AEs). Secondary outcome measures included glaucoma medication use.
Overall, 101 patients were implanted with the MicroShunt. Baseline mean ± standard deviation IOP and medications/patient were 21.5±4.2 mmHg and 2.2±1.3, respectively. At Month 12, IOP was 14.9±4.4 mmHg (27% reduction; data not censored for failed cases; n=89); 70% of patients had overall success. At Month 12, 67% of patients were medication free. Before Month 12, there with 13 bleb revisions, with one conversion to trabeculectomy and two conversions to Baerveldt devices. The most common AEs were hypotony (10%) and shallow chambers (5%); both of which resolved spontaneously. Ten needlings (10%) were reported. There were no reports of long-term sight-threatening AEs.
These interim 12-month results support previous studies; the MicroShunt decreased IOP and the number of glaucoma medications with an acceptable safety and tolerability profile.Sponsored by InnFocus, a Santen company.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only